Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients by Generali, D, Fox, S, Buffa, F, Berruti, A, Brizzi, M, Allevi, G, Bonardi, S, Dogliotti, L, Bottini, A, Harris, A

Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients. by Generali, D, Fox, S, Buffa, F, Berruti, A, Brizzi, M, Allevi, G, Bonardi, S, Dogliotti, L, Bottini, A, Harris, A

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design. by Generali, D, Berruti, A, Foroni, C, Bazzola, L, Andreis, D, Allevi, G, Bersiga, A, Dogliotti, L, Fox, S, Harris, A, Bottini, A

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to pri... by Fox, S, Generali, D, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Mele, T, Dogliotti, L, Bottini, A, Harris, A

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. by Mele, T, Generali, D, Fox, S, Brizzi, M, Bersiga, A, Milani, M, Allevi, G, Bonardi, S, Aguggini, S, Volante, M, Dogliotti, L, Bottini, A, Harris, A, Berruti, A

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients by Mele, T, Generali, D, Fox, S, Brizzi, M, Bersiga, A, Milani, M, Allevi, G, Bonardi, S, Aguggini, S, Volante, M, Dogliotti, L, Bottini, A, Harris, A, Berruti, A

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to pri... by Fox, S, Generali, D, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Mele, T, Dogliotti, L, Bottini, A, Harris, A

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer by Generali, D, Fox, S, Berruti, A, Moore, J, Brizzi, M, Patel, N, Allevi, G, Bonardi, S, Aguggini, S, Bersiga, A, Campo, L, Dogliotti, L, Bottini, A, Harris, A

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. by Generali, D, Fox, S, Berruti, A, Moore, J, Brizzi, M, Patel, N, Allevi, G, Bonardi, S, Aguggini, S, Bersiga, A, Campo, L, Dogliotti, L, Bottini, A, Harris, A

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. by Generali, D, Buffa, F, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Papotti, M, Dogliotti, L, Bottini, A, Harris, A, Fox, S

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. by Generali, D, Bates, G, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Dogliotti, L, Banham, A, Harris, A, Bottini, A, Fox, S

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. by Generali, D, Dovio, A, Tampellini, M, Tucci, M, Tedoldi, S, Torta, M, Bonardi, S, Allevi, G, Aguggini, S, Milani, M, Harris, A, Bottini, A, Dogliotti, L, Angeli, A, Berruti, A

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. by Generali, D, Fox, S, Brizzi, M, Allevi, G, Bonardi, S, Aguggini, S, Milani, M, Bersiga, A, Campo, L, Dionisio, R, Vergoni, F, Giardini, R, Dogliotti, L, Bottini, A, Harris, A, Berruti, A

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer by Allevi, G, Strina, C, Andreis, D, Zanoni, V, Bazzola, L, Bonardi, S, Foroni, C, Milani, M, Cappelletti, MR, Gussago, F, Aguggini, S, Giardini, R, Martinotti, M, Fox, S, Harris, A, Bottini, A, Berruti, A, Generali, D

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. by Allevi, G, Strina, C, Andreis, D, Zanoni, V, Bazzola, L, Bonardi, S, Foroni, C, Milani, M, Cappelletti, MR, Gussago, F, Aguggini, S, Giardini, R, Martinotti, M, Fox, S, Harris, A, Bottini, A, Berruti, A, Generali, D

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer by Andreis, D, Bonardi, S, Allevi, G, Aguggini, S, Gussago, F, Milani, M, Strina, C, Spada, D, Ferrero, G, Ungari, M, Rocca, A, Nanni, O, Roviello, G, Berruti, A, Harris, A, Fox, S, Roviello, F, Polom, K, Bottini, A, Generali, D